Skip to main content

Advertisement

SpringerLink
Log in

Pharmacodynamic Model of Parathyroid Hormone Modulation by a Negative Allosteric Modulator of the Calcium-Sensing Receptor

  • Research Article
  • Theme: Pharmacokinetic/Pharmadynamic Modeling and Simulation in Drug Discovery and Translational Research
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

In this study, a pharmacodynamic model is developed, based on calcium–parathyroid hormone (PTH) homeostasis, which describes the concentration–effect relationship of a negative allosteric modulator of the calcium-sensing receptor (CaR) in rats. Plasma concentrations of drug and PTH were determined from plasma samples obtained via serial jugular vein sampling following single subcutaneous doses of 1, 5, 45, and 150 mg/kg to male Sprague–Dawley rats (n = 5/dose). Drug pharmacokinetics was described by a one-compartment model with first-order absorption and linear elimination. Concentration-time profiles of PTH were characterized using a model in which the compound allosterically modulates Ca+2 binding to the CaR that, in turn, modulates PTH through a precursor-pool indirect response model. Additionally, negative feedback was incorporated to account for tolerance observed at higher dose levels. Model fitting and parameter estimation were conducted using the maximum likelihood algorithm. The proposed model well characterized the data and provided compound specific estimates of the K i and cooperativity constant (α) of 1.47 ng/mL and 0.406, respectively. In addition, the estimated model parameters for PTH turnover were comparable to that previously reported. The final generalized model is capable of characterizing both PTH–Ca+2 homeostasis and the pharmacokinetics and pharmacodynamics associated with the negative allosteric CaR modulator. As such, the model provides a simple platform for analysis of drugs targeting the PTH–Ca+2 system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Tarantino U, Cannata G, Lecce D, Celi M, Cerocchi I, Iundusi R. Incidence of fragility fractures. Aging Clin Exp Res. 2007;19(4 Suppl):7–11.

    PubMed  Google Scholar 

  2. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359(9319):1761–7.

    Article  PubMed  Google Scholar 

  3. Department of Health and Human Services US. Bone health and osteoporosis: a report of the surgeon general: Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General. 2004.

  4. Friedman PA. Agents affecting mineral ion homeostasis and bone turnover. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th edn. New York McGraw-Hill Medical Publishing Division; 2006.

  5. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350(9077):550–5.

    Article  PubMed  CAS  Google Scholar 

  6. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J. 1980;280(6228):1340–4.

    Article  PubMed  CAS  Google Scholar 

  7. Reeve J, Tregear GW, Parsons JA. Preliminary trial of low doses of human parathyroid hormone 1–34 peptide in treatment of osteoporosis. Calcif Tissue Res. 1976;21(Suppl):469–77.

    PubMed  Google Scholar 

  8. Black DM, Bouxsein ML, Palermo L, McGowan JA, Newitt DC, Rosen E, et al. Randomized trial of once-weekly parathyroid hormone (1–84) on bone mineral density and remodeling. J Clin Endocrinol Metab. 2008;93(6):2166–72.

    Article  PubMed  CAS  Google Scholar 

  9. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41.

    Article  PubMed  CAS  Google Scholar 

  10. Juppner HW, Gardella TJ, Brown EM, Kronenberg HM, Potts Jr JT. Parathyroid hormone and parathyroid hormone-related peptide in the regulation of calcium homeostasis and bone development. In: DeGroot LJ, Jameson JL, editors. Endocrinology. Philadelphia: Saunders; 2001. p. 969–98.

    Google Scholar 

  11. Friedman PA, Goodman WG. PTH(1–84)/PTH(7–84): a balance of power. Am J Physiol Ren Physiol. 2006;290(5):F975–84.

    Article  CAS  Google Scholar 

  12. Chen RA, Goodman WG. Role of the calcium-sensing receptor in parathyroid gland physiology. Am J Physiol Ren Physiol. 2004;286(6):F1005–11.

    Article  CAS  Google Scholar 

  13. Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest. 2000;105(11):1595–604.

    Article  PubMed  CAS  Google Scholar 

  14. Nemeth EF, Delmar EG, Heaton WL, Miller MA, Lambert LD, Conklin RL, et al. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther. 2001;299(1):323–31.

    PubMed  CAS  Google Scholar 

  15. Marquis RW, Lago AM, Callahan JF, Rahman A, Dong X, Stroup GB, et al. Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues. J Med Chem. 2009;52(21):6599–605.

    Article  PubMed  CAS  Google Scholar 

  16. Marquis RW, Lago AM, Callahan JF, Trout RE, Gowen M, DelMar EG, et al. Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues. J Med Chem. 2009;52(13):3982–93.

    Article  PubMed  CAS  Google Scholar 

  17. Arey BJ, Seethala R, Ma Z, Fura A, Morin J, Swartz J, et al. A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. Endocrinology. 2005;146(4):2015–22.

    Article  PubMed  CAS  Google Scholar 

  18. Balan G, Bauman J, Bhattacharya S, Castrodad M, Healy DR, Herr M, et al. The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg Med Chem Lett. 2009;19(12):3328–32.

    Article  PubMed  CAS  Google Scholar 

  19. Kumar S, Matheny CJ, Hoffman SJ, Marquis RW, Schultz M, Liang X, et al. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone. 2010;46(2):534–42.

    Article  PubMed  CAS  Google Scholar 

  20. Lotinun S, Sibonga JD, Turner RT. Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Endocrine. 2002;17(1):29–36.

    Article  PubMed  CAS  Google Scholar 

  21. Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1–34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997;138(11):4607–12.

    Article  PubMed  CAS  Google Scholar 

  22. Frolik CA, Black EC, Cain RL, Satterwhite JH, Brown-Augsburger PL, Sato M, et al. Anabolic and catabolic bone effects of human parathyroid hormone (1–34) are predicted by duration of hormone exposure. Bone. 2003;33(3):372–9.

    Article  PubMed  CAS  Google Scholar 

  23. Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab. 1983;56(3):572–81.

    Article  PubMed  CAS  Google Scholar 

  24. Momsen G, Schwarz P. A mathematical/physiological model of parathyroid hormone secretion in response to blood-ionized calcium lowering in vivo. Scand J Clin Lab Investig. 1997;57(5):381–94.

    Article  CAS  Google Scholar 

  25. Raposo JF, Sobrinho LG, Ferreira HG. A minimal mathematical model of calcium homeostasis. J Clin Endocrinol Metab. 2002;87(9):4330–40.

    Article  PubMed  CAS  Google Scholar 

  26. Abraham AK, Mager DE, Gao X, Li M, Healy DR, Maurer TS. Mechanism-based pharmacokinetic/pharmacodynamic model of parathyroid hormone-calcium homeostasis in rats and humans. J Pharmacol Exp Ther. 2009;330(1):169–78.

    Article  PubMed  CAS  Google Scholar 

  27. Van Wagenen BC, Del Mar EG, Sheehan D, Barmore RM, Keenan RM, Kotecha NR, et al., inventors; Calcilytic Compounds patent WO 97/37967 A1. 1997.

  28. Sharma A, Ebling WF, Jusko WJ. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci. 1998;87(12):1577–84.

    Article  PubMed  CAS  Google Scholar 

  29. Martin KJ, Hruska KA, Lewis J, Anderson C, Slatopolsky E. The renal handling of parathyroid hormone. Role of peritubular uptake and glomerular filtration. J Clin Invest. 1977;60(4):808–14.

    Article  PubMed  CAS  Google Scholar 

  30. Daugaard H, Egfjord M, Olgaard K. Metabolism of parathyroid hormone in isolated perfused rat kidney and liver combined. Kidney Int. 1990;38(1):55–62.

    Article  PubMed  CAS  Google Scholar 

  31. Nemeth EF. Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Des. 2002;8(23):2077–87.

    Article  PubMed  CAS  Google Scholar 

  32. Chattopadhyay N. Biochemistry, physiology and pathophysiology of the extracellular calcium-sensing receptor. Int J Biochem Cell Biol. 2000;32(8):789–804.

    Article  PubMed  CAS  Google Scholar 

  33. Kenakin T. Allosteric modulators: the new generation of receptor antagonist. Mol Interv. 2004;4(4):222–9.

    Article  PubMed  CAS  Google Scholar 

  34. Kenakin T. Allosteric drug antagonism. A pharmacology primer: theory, application, and method 2nd edn: Academic Press; 2006. p. 127–46.

  35. Ehlert FJ. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol. 1988;33(2):187–94.

    PubMed  CAS  Google Scholar 

  36. D’Argenio D, Schumitzky A. ADAPT II user’s guide. Los Angeles: Biomedical Simulations Resource; 1997.

    Google Scholar 

  37. Hu J, Reyes-Cruz G, Goldsmith PK, Spiegel AM. The Venus’s-flytrap and cysteine-rich domains of the human Ca2+ receptor are not linked by disulfide bonds. J Biol Chem. 2001;276(10):6901–4.

    Article  PubMed  CAS  Google Scholar 

  38. Brown EM. Calcium receptor and regulation of parathyroid hormone secretion. Rev Endocr Metab Disord. 2000;1(4):307–15.

    Article  PubMed  CAS  Google Scholar 

  39. Ostrowska Z, Kos-Kudla B, Marek B, Kajdaniuk D, Ciesielska-Kopacz N. The relationship between the daily profile of chosen biochemical markers of bone metabolism and melatonin and other hormone secretion in rats under physiological conditions. Neuro Endocrinol Lett. 2002;23(5–6):417–25.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was funded, in part, by the University at Buffalo–Pfizer Strategic Alliance.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Amherst, New York, USA

    Anson K. Abraham & Donald E. Mager

  2. Pharmacokinetics, Pharmacodynamics and Metabolism Department, Pfizer Inc., Eastern Point Road, Groton, Connecticut, 06340, USA

    Tristan S. Maurer & Amit S. Kalgutkar

  3. Clinical Pharmacology, Pfizer Inc., New London, Connecticut, USA

    Xiang Gao

  4. Biology Department, Healthy Aging Translational Pharmacology, Pfizer Inc., Groton, Connecticut, USA

    Mei Li, David R. Healy & Donna N. Petersen

  5. Chemistry Department, Healthy Aging Translational Pharmacology, Pfizer Inc., Groton, Connecticut, USA

    David A. Griffith

Authors
  1. Anson K. Abraham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tristan S. Maurer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amit S. Kalgutkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiang Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David R. Healy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Donna N. Petersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David A. Griffith
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Donald E. Mager
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tristan S. Maurer.

Additional information

Guest Editors: Cheryl Li, Pratap Singh, and Anjaneya Chimalakonda

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abraham, A.K., Maurer, T.S., Kalgutkar, A.S. et al. Pharmacodynamic Model of Parathyroid Hormone Modulation by a Negative Allosteric Modulator of the Calcium-Sensing Receptor. AAPS J 13, 265–273 (2011). https://doi.org/10.1208/s12248-011-9266-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-011-9266-9

KEY WORDS

Search

Navigation